Engineering the best transplant outcome for high-risk acute myeloid leukemia: The donor, the graft and beyond Review
| Authors: | Belbachir, S.; Abraham, A.; Sharma, A.; Prockop, S.; DeZern, A. E.; Bonfim, C.; Bidgoli, A.; Li, J.; Ruggeri, A.; Bertaina, A.; Boelens, J. J.; Purtill, D.; on behalf of the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy |
| Review Title: | Engineering the best transplant outcome for high-risk acute myeloid leukemia: The donor, the graft and beyond |
| Abstract: | Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or severe graft-versus-host disease remains a critical area of unmet need. Recently, significant progress has been made in the cell therapy-based interventions both before and after transplant. In this review, the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy summarizes the literature regarding the identification of high risk in AML, treatment approaches before transplant, optimal transplant platforms and measures that may be taken after transplant to ideally prevent, or, if need be, treat AML relapse. Although some strategies remain in the early phases of clinical investigation, they are built on progress in pre-clinical research and cellular engineering techniques that are already improving outcomes for children and adults with high-risk malignancies. © 2023 International Society for Cell & Gene Therapy |
| Keywords: | treatment outcome; transplantation, homologous; leukemia, myeloid, acute; t lymphocyte; bone marrow; maintenance therapy; cyclophosphamide; hematopoietic stem cell transplantation; high risk patient; donor; tissue donors; genetic engineering; graft versus host reaction; donor lymphocyte infusion; allogeneic hematopoietic stem cell transplantation; cell therapy; natural killer cell; umbilical cord blood; t cell depletion; immunosuppressive treatment; leukemia relapse; graft vs host disease; ex vivo study; therapy; allotransplantation; thymocyte antibody; leukemia remission; unrelated donor; acute myeloid leukemia; procedures; allogeneic peripheral blood stem cell transplantation; cell engineering; conditioning chemotherapy; humans; human; article; pediatric patient; haploidentical donor; matched sibling donor; novel cellular therapies |
| Journal Title: | Cytotherapy |
| Volume: | 26 |
| Issue: | 6 |
| ISSN: | 1465-3249 |
| Publisher: | Elsevier Science Ltd. |
| Date Published: | 2024-06-01 |
| Start Page: | 546 |
| End Page: | 555 |
| Language: | English |
| DOI: | 10.1016/j.jcyt.2023.11.004 |
| PUBMED: | 38054912 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
